In keeping with current guidelines, either empagliflozin or dapagliflozin can be used for preventing AKI and CKD in patients with type 2 diabetes. Empagliflozin and dapagliflozin are equally effective ...
Among a small cohort of healthy Korean male volunteers, evogliptin combined with empagliflozin or dapagliflozin had no significant effects on the pharmacokinetics (PK) of each drug. In healthy male ...
Comparative effectiveness study followed adults with type 2 diabetes who initiated SGLT-2 inhibitors from 2014 to 2020. Real-world outcomes largely point to comparable risks of hospitalization for ...
The SGLT2 inhibitors, as a class, lead to similar treatment benefits at comparable clinical doses, although there are some discrepancies between them, particularly when dapagliflozin (Farxiga; ...
Researchers conducted a target trial emulation using Danish healthcare data to compare the effectiveness of empagliflozin and dapagliflozin in improving kidney outcomes among patients with T2D. They ...
NATIONAL HARBOR, Md. -- The benefits of dapagliflozin (Farxiga) persisted in various secondary analyses of the DELIVER trial, building confidence for real-world benefits from the SGLT2 inhibitor for ...
In April 2021, dapagliflozin (Farxiga) received a new indication from the US Food and Drug Administration (FDA) for slowing progression of chronic kidney disease (CKD) in people without any other ...
Please provide your email address to receive an email when new articles are posted on . In adults with HF with mildly reduced or preserved ejection fraction, dapagliflozin significantly reduced risk ...
The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback